Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

NEJM Examines Several Health Issues In Perspective Pieces
The New England Journal of Medicine published a series of perspectives that examine a variety of topics--from the struggle to finance health care reform to vaccine issues, the Food and Drug Administration and prescription drug marketing legislation in Vermont. The collection of perspectives includes a piece by Jonathan Gruber, PhD., "A Win-Win Approach to Financing Health Care Reform" and John K. Iglehart"s examination of Democrat"s challenge to securing money in "Finding Money for Health Care Reform - Rooting Out Waste, Fraud, and Abuse." Another piece, this one by Robert Steinbrook, M.D., examines new legislation in Vermont amid the background of reform of physician-industry relations in his piece "A Higher Bar - Vermont"s New Law on Marketing Prescribed Products."

Second U.S. Independent Laboratory Confirms That Oculus Innovative Sciences' Microcyn(R) Technology Effective At Inactivating H1N1 Swine Flu
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which includes new formulations intended to reduce the use of antibiotics by preventing or treating infections including those caused by bacteria and viruses, has confirmed the effectiveness of Microcyn® Technology at inactivating the H1NI Swine Influenza A. In a virucidal time-kill suspension test conducted by an independent laboratory, BioScience Laboratories, Inc., the specific Microcyn Technology formulation reduced infectivity of the swine flu virus by 4.00log10 (99.99%) reduction after just 30-seconds exposure. BioScience Laboratories, working in cooperation with the U.S. Department of Agriculture, received formal approval to acquire, house and evaluate the specific swine influenza virus in April 2009.
News of the day
FDA Reviewing Preliminary Safety Information On Asthma Drug Xolair
The U.S. Food and Drug Administration announced that it is conducting a safety review of Xolair (omalizumab), a drug used to treat certain adults and adolescents with moderate-to-severe persistent asthma.
Mental Health

BIO Commends Senate Committee On Small Business And Entrepreneurship's SBIR Reauthorization

Under legislation reported by the Senate Committee on Small Business and Entrepreneurship, small companies that receive the majority of their financing from venture capital will once again be considered eligible to compete for Small Business Innovation Research (SBIR) grants. The change will allow more small biotechnology start-ups to compete for these funds and continue critical research and development of medical advancements and breakthroughs. Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood made the following statement today: "For six years, more than half of all small private U.S. biotech companies have not been allowed to compete for SBIR grants due to a bureaucratic ruling. Especially in these troubling economic times, these federal grants could provide considerable support for small companies and the patients awaiting development of new therapies. "I commend the Senate Committee on Small Business and Entrepreneurship, Chairwoman Mary Landrieu, and Ranking Member Olympia Snowe on their hard work to move this process forward. This legislation provides the opportunity for biotech companies to compete on the promise of their science rather than how they are financed. Over 90 percent of the biotech industry is comprised of small businesses engaged in high risk, high reward research and development that benefits us all. "I urge Congress and the Administration to reauthorize the SBIR program as soon as possible in a way that provides a level playing field for all small companies, regardless of their capital structure. I look forward to working with Members of the House and Senate to modernize the SBIR program to reflect the business realities facing small companies in capital-intensive industries, such as biotechnology. And to do so in a way that does not artificially limit the participation of some of our nation"s most innovative and promising small businesses." As a result of the Small Business Administration (SBA)"s reinterpretation of the program"s eligibility requirements in 2003, the applicant pool at the National Institutes of Health (NIH) for SBIR grants has been shrinking. For example, when they became ineligible for SBIR grants, several small biotech firms stopped their work aimed at developing new treatments for cancer and cystic fibrosis. Two years later, NIH Director Elias A. Zerhouni, M.D. told the SBA that limits on SBIR eligibility, "unduly restrict the ability of the NIH to fund high quality, small companies." He expressed concern that the eligibility requirement "undermines NIH"s ability to award SBIR funds to those applicants whom we believe are most likely to improve human health." Patient advocacy groups also have expressed concern about the eligibility restrictions. Sixty patient groups sent a letter to leaders of the 110th Congress in support of reinstating the eligibility of small biotech firms to compete for SBIR grants. In the letter, they asked Congress to "help innovative research move forward in order to foster breakthrough cures. See BIO"s web site and SBIR blog at http://www.hopesandcures.org. BIO


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009